Pembrolizumab: all 1,753 studies that test it

Page 15 of 18. Open to participants first (418), then studies with results posted, then the rest; newest registration first within each.

• Pre-Operative Pembrolizumab + Chemoradiation in Patients With Locally Advanced Esophageal Squamous Cell CarcinomaCompletedNCT04435197Phase 2
• AN0025 and Pembrolizumab Combination in Advanced Solid TumorsActive, not recruitingNCT04432857Phase 1
• Cisplatin+Pembrolizumab+RT in Vulvar CancerActive, not recruitingNCT04430699Phase 2
• Preoperative Lenvatinib Plus Pembrolizumab in Early-Stage Triple-Negative Breast Cancer (TNBC)Active, not recruitingNCT04427293Phase 1
• Pembrolizumab and LENvatinib in Participants With Hepatocellular Carcinoma (HCC) Before Liver TransplantStatus unknownNCT04425226Not applicable
• Breast Cancer Vaccine in Combination With Pembrolizumab for Treatment of Persistent, Recurrent, or Metastatic Breast CancerWithdrawnNCT04418219Phase 1/2
• Olaparib Monotherapy and Olaparib + Pembrolizumab Combination Therapy for Ovarian CancerCompletedNCT04417192Phase 2
• Pembrolizumab and Radiotherapy for Patients With NK/T Cell LymphomaActive, not recruitingNCT04417166Phase 2
• Pembrolizumab Plus Pemetrexed for Elderly Patients With Non-Sq NSCLC With PD-L1 < 50%: CJLSG1901Status unknownNCT04396457Phase 2
• Pembrolizumab Plus Paclitaxel, Cisplatin Followed by Surgery for Locally Advanced ESCC (KEYSTONE-001)Status unknownNCT04389177Phase 2
• Study of CG0070 Given in Combination With Pembrolizumab, in Non-Muscle Invasive Bladder Cancer, Unresponsive to Bacillus Calmette-GuerinCompletedNCT04387461Phase 2
• Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal CancerCompletedNCT04387227Phase 2
• Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin MalignancyActive, not recruitingNCT04387084Phase 1
• Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012)Active, not recruitingNCT04380636Phase 3
• Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma Which Produces Too Much Stress Hormone (Cortisol)CompletedNCT04373265Phase 1
• RTX-240 Monotherapy and in Combination With PembrolizumabTerminatedNCT04372706Phase 1/2
• Study of Dara-Pembro for Multiple Myeloma PatientsWithdrawnNCT04361851Phase 2
• Lurbinectedin (PM01183) Combined With Pembrolizumab in Small Cell Lung Cancer.CompletedNCT04358237Phase 1/2
• Efficacy of Immunotherapy Plus a Drug in Patients With Progressive Advanced Mucosal Cancer of Different LocationsCompletedNCT04357873Phase 2
• Safety and Feasibility of PD-1 Blockade in the Treatment of dMMR or MSI-H Rectal CancerCompletedNCT04357587Phase 1
• Phase 1a/1b Study of TPST-1495 as a Single Agent and in Combination With Pembrolizumab in Subjects With Solid TumorsCompletedNCT04344795Phase 1
• Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 BlockadeActive, not recruitingNCT04340882Phase 2
• Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCCActive, not recruitingNCT04340258Phase 1/2
• NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBCActive, not recruitingNCT04335669Phase 3
• Checkpoint Blockade in COVID-19 PandemicTerminatedNCT04335305Phase 2
• Neoadjuvant-Adjuvant Pembrolizumab in Resectable Advanced Basal Cell Carcinoma of H&NCompletedNCT04323202Phase 1
• Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)CompletedNCT04305054Phase 1/2
• Phase 2 Trial for Chemo-Resistant Gestational Trophoblastic Neoplasias With Pembrolizumab (CR-GTP)Status unknownNCT04303884Phase 2
• Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid TumorsTerminatedNCT04301011Phase 1
• Safety Study of BJ-001, an IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid TumorsActive, not recruitingNCT04294576Phase 1
• Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma PatientsActive, not recruitingNCT04287829Phase 2
• A Phase Ib Combination Study of Rituximab, TinostamustinEAnd CHeckpoint Inhibition With Pembrolizumab in Relapsed/Refractory DLBCLWithdrawnNCT04279938Phase 1
• Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With PembrolizumabSuspendedNCT04266730Phase 1
• Safety and Efficacy of IMC-F106C as a Single Agent and in Combination With Checkpoint InhibitorsActive, not recruitingNCT04262466Phase 1/2
• The CAPER Trial: A Phase Ib Clinical Trial of Cyclophosphamide And PEmbrolizumab in Metastatic Renal Cell CarcinomaStatus unknownNCT04262427Phase 1/2
• Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility StudyCompletedNCT04262089Phase 1
• Study of PDS0101 and Pembrolizumab Combination I/O in Subjects With HPV16 + Recurrent and/or Metastatic HNSCCCompletedNCT04260126Phase 2
• A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTEWithdrawnNCT04258683Phase 2
• Pembrolizumab + Capecitabine／Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 PositiveActive, not recruitingNCT04249739Phase 2
• Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Chemoradiotherapy (CRT) Versus CRT Alone in Muscle-invasive Bladder Cancer (MIBC) (MK-3475-992/KEYNOTE-992)Active, not recruitingNCT04241185Phase 3
• Carboplatin-Paclitaxel-Pembrolizumab in Neoadjuvant Treatment of Locally Advanced Cervical CancerStatus unknownNCT04238988Phase 2
• Pembrolizumab in Early Stage Colon CancerWithdrawnNCT04231526Phase 2
• Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
• Consolidation Pembrolizumab After Chemoradiotherapy in Locally Advanced Nasopharyngeal CarcinomaCompletedNCT04227509Phase 2
• Pembrolizumab Combined With Cisplatin-based Chemotherapy as First-line Systemic Therapy in Advanced Penile CancerCompletedNCT04224740Phase 2
• Longitudinal Immune-phenotyping of HCC Following MK-3475Active, not recruitingNCT04224480Phase 1
• Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial CancerActive, not recruitingNCT04214067Phase 3
• Pembrolizumab in Pre Neoplastic High Grade HPV-related Vulvar and Cervical LesionsStatus unknownNCT04211103Phase 2
• Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)CompletedNCT04210115Phase 3
• Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
• ENB003 Plus Pembrolizumab Phase 1b/2a in Solid TumorsActive, not recruitingNCT04205227Phase 1/2
• Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent GlioblastomaCompletedNCT04201873Phase 1
• Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2
• HFHS-1801-A Pilot Study of Immunotherapy As Consolidation Therapy for Patients with Recurrent Head and Neck CancerCompletedNCT04188951Early Phase 1
• LITT and Pembrolizumab in Recurrent Brain MetastasisTerminatedNCT04187872Phase 1
• Study of Pembrolizumab and Ramucirumab in Pts With Progressive TCC After Treatment With an Immune Checkpoint InhibitorWithdrawnNCT04179110Phase 2
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Testing the Addition of an Anti-cancer Drug, Pembrolizumab, to the Usual Intravesical Chemotherapy Treatment (Gemcitabine) for the Treatment of BCG-Unresponsive Non-muscle Invasive Bladder CancerActive, not recruitingNCT04164082Phase 2
• A Study of LY3200882 and Pembrolizumab in Participants With Advanced CancerWithdrawnNCT04158700Phase 1/2
• Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) ≥50% Locally Advanced NSCLCStatus unknownNCT04153734Phase 2
• Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLCActive, not recruitingNCT04140526Phase 1/2
• Study of PD-1 Inhibitors After CD30.CAR T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT04134325Early Phase 1
• Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic MalignancyCompletedNCT04130542Phase 1
• Study Assessing MTD, Safety, Tolerability, PK and Anti-tumor Effects of LNS8801alone and With PembrolizumabActive, not recruitingNCT04130516Phase 1/2
• NovoTTF-200A + Pembrolizumab In Melanoma Brain MetastasisWithdrawnNCT04129515Phase 1/2
• Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the Treatment of Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer (MK-7339-007/KEYLYNK-007)CompletedNCT04123366Phase 2
• Rintatolimod and Pembrolizumab for the Treatment of Refractory Metastatic or Unresectable Colorectal CancerWithdrawnNCT04119830Phase 2
• Abemaciclib + Pembrolizumab In GlioblastomaWithdrawnNCT04118036Phase 2
• Fecal Microbiota Transplant and Pembrolizumab for Men With Metastatic Castration Resistant Prostate Cancer.Status unknownNCT04116775Phase 2
• A Study of MTL-CEBPA in Combination With a PD-1 Inhibitor in Patients With Advanced Solid Tumours (TIMEPOINT)CompletedNCT04105335Phase 1
• A Study of CHeckpoint Inhibitors in Men With prOgressive Metastatic Castrate Resistant Prostate Cancer Characterized by a Mismatch Repair Deficiency or Biallelic CDK12 InactivationActive, not recruitingNCT04104893Phase 2
• Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the DrugCompletedNCT04095273Phase 1
• Study of CTDNA Response Adaptive Immuno-Chemotherapy in Lung CancerActive, not recruitingNCT04093167Phase 2/3
• Treatment of PD-1 Inhibitor in AIDS-associated PMLStatus unknownNCT04091932Phase 2
• GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic AdenocarcinomaTerminatedNCT04060342Phase 1
• Pembrolizumab and PEGPH20 in Treating Patients With Metastatic Pancreatic CancerWithdrawnNCT04058964Phase 2
• AMD3100 Plus Pembrolizumab in Immune Checkpoint Blockade Refractory Head and Neck Squamous Cell CarcinomaWithdrawnNCT04058145Phase 2
• Phase 1b/II Trial of Pembrolizumab Plus IMRT in Stage III/IV Carcinoma of AnusActive, not recruitingNCT04046133Phase 1
• DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung CancerActive, not recruitingNCT04042701Phase 1
• Establishing the Recommended Biological Dose for AE37 Peptide Vaccine in Combination With Pembrolizumab That Will Enhance the Tumor-specific Immune Response and Demonstrate Efficacy in Patients With Advanced Triple-negative Breast CancerStatus unknownNCT04024800Phase 2
• Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO StudyStatus unknownNCT04014530Phase 1/2
• Biomarkers for Neoadjuvant Pembrolizumab in Non-Metastatic Prostate Cancer Positive by 18FDG-PET ScanningActive, not recruitingNCT04009967Phase 2
• Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid TumorsActive, not recruitingNCT04007744Phase 1
• Pembrolizumab in Combination With Chemotherapy for Patients With Untreated B Cell LymphomaActive, not recruitingNCT03995147Phase 2
• Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung CancerActive, not recruitingNCT03991819Phase 1
• Study of Pembrolizumab in Metastatic HER2-negative Breast Cancer Patients With APOBEC3B MutationActive, not recruitingNCT03989089Phase 2
• A Study With Pembrolizumab in Combination With Dual Anti-HER2 Blockade With Trastuzumab and Pertuzumab in Early Breast Cancer Patients With Molecular HER2-enriched Intrinsic Subtype (Keyriched-1)CompletedNCT03988036Phase 2
• Window of Opportunity Study in Colorectal CancerCompletedNCT03984578Phase 2
• Epicutaneous Cryoimmunotherapy Combined With Pembrolizumab for Cutaneous Metastatic Breast CancerTerminatedNCT03982004Phase 1
• A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedNCT03954067Phase 1
• Androgen Deprivation Therapy (ADT) and Pembrolizumab for Advanced Stage Androgen Receptor-positive Salivary Gland CarcinomaActive, not recruitingNCT03942653Phase 2
• Allogeneic NK Cell ("SMT-NK") in Combination With Pembrolizumab in Advanced Biliary Tract CancerCompletedNCT03937895Phase 1/2
• Adoptive Cell Therapy With (LN-145) in Combination With Pembrolizumab in Treating Patients With Unresectable or Metastatic Transitional Cell Cancer Who Have Failed Cisplatin-Based ChemotherapyWithdrawnNCT03935347Phase 2
• Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and LymphomaCompletedNCT03934814Phase 1
• Frontline Immunotherapy Combined With Radiation and Chemotherapy in High Risk Endometrial CancerActive, not recruitingNCT03932409Phase 1
• Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)CompletedNCT03924856Phase 3
• A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)CompletedNCT03918278Phase 1
• A Trial of BXCL701 and Pembrolizumab in Patients With mCRPC Either Small Cell Neuroendocrine Prostate Cancer or Adenocarcinoma Phenotype.CompletedNCT03910660Phase 1/2

← Pembrolizumab overview